Cite
HARVARD Citation
Rotondo, A. et al. (2019). Randomised clinical trial: the DPP‐4 inhibitor, vildagliptin, inhibits gastric accommodation and increases glucagon‐like peptide‐1 plasma levels in healthy volunteers. Alimentary pharmacology & therapeutics. 49 (8), pp. 997-1004. [Online].